Lenzilumab

DB15148InvestigationalProtein Based Therapies

Lenzilumab is under investigation in clinical trial NCT02546284 (Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)).

Mechanism: Pharmacologically active on Granulocyte-macrophage colony-stimulating factor
Curator reviewed

Resolves to

Compound

UNIIIE4X6497XKCAS1229575-09-0

Targets

P04141CSF2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lenzilumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account